Home › Companies › Forte Biosciences, Inc. › 2025-2026
At Forte Biosciences, Inc.'s shareholder meeting held May 29, 2026, in the 2025-2026 proxy season, 70 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 346 separate fund positions. On the most widely held item on that ballot — The approval, on an advisory basis, of the compensation of the Company's named executive… — Forte Biosciences, Inc.'s filing reports the proposal as approved, with 76% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Forte Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 2, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Forte Biosciences, Inc.’s Form 8-K, filed June 2, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 29, 2026: 6 items on Forte Biosciences, Inc.’s Form 8-K, filed June 2, 2026: 3 elected · 3 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Forte Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Forte Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 2, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Steven Kornfeld | 12,286,043 | -- | -- | 3,973,928 | 1,506,063 | 76% | Elected | — |
| Elect Director: Scott Brun, M.D. | 12,958,889 | -- | -- | 3,301,082 | 1,506,063 | 80% | Elected | — |
| Elect Director: Paul A. Wagner, Ph.D. | 16,027,110 | -- | -- | 232,861 | 1,506,063 | 99% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 17,722,893 | 3,182 | 39,959 | -- | 0 | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation. | 12,143,153 | 3,764,729 | 352,089 | -- | 1,506,063 | 76% | Approved | — |
| 4. Approval of the Amended and Restated 2021 Equity Incentive Plan . | 11,911,879 | 3,997,050 | 351,042 | -- | 1,506,063 | 75% | Approved | — |
Source: Forte Biosciences, Inc., Form 8-K, filed with the SEC on June 2, 2026 — read the filing on EDGAR.
Each item below shows how the 70 asset managers that disclosed a Forte Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) Class III directors to hold office until our 2029 annual meeting of stockholders and until his or her respective successors are elected and qualified: Paul A. Wagner, Ph.D.
Forte Biosciences, Inc.’s own tally for this item (“Elect Director: Paul A. Wagner, Ph.D.”): 16,027,110 for, 232,861 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to serve as Class III directors, each to hold office until the Company's 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 4,829,541 for, 1,184 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| Fidelity | 775,581 | 0 | 0 | 0 | For |
| ALGER FUNDS | 761,825 | 0 | 0 | 0 | For |
| Vanguard | 692,727 | 0 | 0 | 1,117 | For |
| ALGER PORTFOLIOS | 241,730 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 56,452 | 0 | 0 | 0 | For |
| Russell Investments | 50,051 | 0 | 0 | 0 | For |
| Alger ETF Trust | 33,002 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 32,341 | 0 | 0 | 0 | For |
| Lord Abbett | 32,292 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 10,200 | 0 | 0 | 0 | For |
| Charles Schwab | 9,864 | 0 | 0 | 0 | For |
| American Century | 8,576 | 0 | 0 | 0 | For |
| Empower | 6,691 | 0 | 0 | 0 | For |
| Equitable | 5,362 | 0 | 0 | 0 | For |
| Victory Capital | 1,246 | 0 | 0 | 0 | For |
| Texas Capital Funds Trust | 607 | 0 | 0 | 0 | For |
| BlackRock | 268 | 0 | 0 | 0 | For |
| John Hancock | 208 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 67 | Withhold |
| Guggenheim | 2 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
80% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) Class III directors to hold office until our 2029 annual meeting of stockholders and until his or her respective successors are elected and qualified: Scott Brun, M.D.
Forte Biosciences, Inc.’s own tally for this item (“Elect Director: Scott Brun, M.D.”): 12,958,889 for, 3,301,082 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to serve as Class III directors, each to hold office until the Company's 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal:”
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 3,683,954 for, 1,146,766 withheld, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| Fidelity | 775,581 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 0 | 0 | 761,825 | Withhold |
| Vanguard | 692,722 | 0 | 5 | 1,117 | For |
| ALGER PORTFOLIOS | 0 | 0 | 0 | 241,730 | Withhold |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 56,452 | Withhold |
| Russell Investments | 50,051 | 0 | 0 | 0 | For |
| Alger ETF Trust | 0 | 0 | 0 | 33,002 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 32,341 | Withhold |
| Lord Abbett | 32,292 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 10,200 | Withhold |
| Charles Schwab | 9,864 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 8,576 | Withhold |
| Empower | 6,691 | 0 | 0 | 0 | For |
| Equitable | 5,362 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 1,246 | Withhold |
| Texas Capital Funds Trust | 607 | 0 | 0 | 0 | For |
| BlackRock | 268 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 208 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 67 | Withhold |
| Guggenheim | 0 | 0 | 0 | 2 | Withhold |
Combines 3 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Description as filed by funds: To elect three (3) Class III directors to hold office until our 2029 annual meeting of stockholders and until his or her respective successors are elected and qualified: Steven Kornfeld
Forte Biosciences, Inc.’s own tally for this item (“Elect Director: Steven Kornfeld”): 12,286,043 for, 3,973,928 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The following nominees were elected to serve as Class III directors, each to hold office until the Company's 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal:”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 3,622,978 for, 1,207,741 withheld, 6 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| Fidelity | 775,581 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 0 | 0 | 761,825 | Withhold |
| Vanguard | 692,185 | 0 | 6 | 1,653 | For |
| ALGER PORTFOLIOS | 0 | 0 | 0 | 241,730 | Withhold |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 56,452 | Withhold |
| Russell Investments | 0 | 0 | 0 | 50,051 | Withhold |
| Alger ETF Trust | 0 | 0 | 0 | 33,002 | Withhold |
| ALGER FUNDS II | 0 | 0 | 0 | 32,341 | Withhold |
| Lord Abbett | 32,292 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 10,200 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 9,864 | Withhold |
| American Century | 0 | 0 | 0 | 8,576 | Withhold |
| Empower | 6,691 | 0 | 0 | 0 | For |
| Equitable | 5,106 | 0 | 0 | 256 | For |
| Victory Capital | 0 | 0 | 0 | 1,246 | Withhold |
| Texas Capital Funds Trust | 607 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 268 | Withhold |
| John Hancock | 0 | 0 | 0 | 208 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 67 | Withhold |
| Guggenheim | 0 | 0 | 0 | 2 | Withhold |
75% Approved · of votes cast
Description as filed by funds: THE APPROVAL OF THE COMPANY'S AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN.
Forte Biosciences, Inc.’s own tally for this item (“4. Approval of the Amended and Restated 2021 Equity Incentive Plan .”): 11,911,879 for, 3,997,050 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the A&R 2021 Equity Incentive Plan.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| Fidelity | 149,390 | 626,191 | 0 | 0 | Mixed |
| ALGER FUNDS | 0 | 761,825 | 0 | 0 | Against |
| Vanguard | 692,721 | 1,123 | 0 | 0 | For |
| ALGER PORTFOLIOS | 0 | 241,730 | 0 | 0 | Against |
| ALGER INSTITUTIONAL FUNDS | 0 | 56,452 | 0 | 0 | Against |
| Russell Investments | 50,051 | 0 | 0 | 0 | For |
| Alger ETF Trust | 0 | 33,002 | 0 | 0 | Against |
| ALGER FUNDS II | 0 | 32,341 | 0 | 0 | Against |
| Lord Abbett | 32,292 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 10,200 | 0 | 0 | Against |
| Charles Schwab | 9,864 | 0 | 0 | 0 | For |
| American Century | 0 | 8,576 | 0 | 0 | Against |
| Empower | 6,691 | 0 | 0 | 0 | For |
| Equitable | 5,362 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 1,246 | 0 | 0 | Against |
| Texas Capital Funds Trust | 607 | 0 | 0 | 0 | For |
| BlackRock | 268 | 0 | 0 | 0 | For |
| John Hancock | 0 | 208 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 67 | 0 | 0 | Against |
| Guggenheim | 0 | 2 | 0 | 0 | Against |
Fund voting reports, all 21 managers: 3,057,762 for, 1,772,963 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Integral Health Asset Management, LLC | 315,802 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 315,802 for.
Combines 7 wordings of this item as funds reported it.
76% Approved · of votes cast
Description as filed by funds: The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote").
Forte Biosciences, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation.”): 12,143,153 for, 3,764,729 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025.”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| Fidelity | 626,191 | 149,390 | 0 | 0 | Mixed |
| ALGER FUNDS | 0 | 761,825 | 0 | 0 | Against |
| Vanguard | 693,302 | 541 | 0 | 0 | For |
| ALGER PORTFOLIOS | 0 | 241,730 | 0 | 0 | Against |
| ALGER INSTITUTIONAL FUNDS | 0 | 56,452 | 0 | 0 | Against |
| Russell Investments | 0 | 50,051 | 0 | 0 | Against |
| Alger ETF Trust | 0 | 33,002 | 0 | 0 | Against |
| ALGER FUNDS II | 0 | 32,341 | 0 | 0 | Against |
| Lord Abbett | 32,292 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 10,200 | 0 | 0 | Against |
| Charles Schwab | 0 | 9,864 | 0 | 0 | Against |
| American Century | 0 | 8,576 | 0 | 0 | Against |
| Empower | 6,691 | 0 | 0 | 0 | For |
| Equitable | 5,362 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 1,246 | 0 | 0 | Against |
| Texas Capital Funds Trust | 607 | 0 | 0 | 0 | For |
| BlackRock | 268 | 0 | 0 | 0 | For |
| John Hancock | 0 | 208 | 0 | 0 | Against |
| Advisors' Inner Circle Fund III | 0 | 67 | 0 | 0 | Against |
| Guggenheim | 0 | 2 | 0 | 0 | Against |
Fund voting reports, all 21 managers: 3,475,229 for, 1,355,495 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 2,730,920 | 0 | 0 | 0 | For |
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,577,705 | 0 | 0 | 0 | For |
| FRED ALGER MANAGEMENT, LLC | 0 | 1,252,139 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 969,368 | 0 | 0 | Against |
| MPM BioImpact LLC | 951,388 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 896,559 | 0 | 0 | 0 | For |
| Woodline Partners LP | 822,348 | 0 | 0 | 0 | For |
| Fidelity | 626,191 | 0 | 0 | 0 | For |
| Citadel | 482,435 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 316,839 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 315,802 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 192,196 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 187,571 | 0 | 0 | Against |
| Trails Edge Capital Partners, LP | 185,000 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 134,592 | 0 | 0 | 0 | For |
| Vanguard | 111,556 | 0 | 0 | 0 | For |
| J. Goldman & Co LP | 87,202 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 85,015 | 0 | 0 | Against |
| State Street | 78,499 | 1,522 | 0 | 0 | For |
| BlackRock | 70,431 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 58,768 | 2,119 | 0 | 0 | For |
| Boxer Capital Management, LLC | 53,239 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 50,808 | 0 | 0 | Against |
| Logos Global Management LP | 0 | 50,000 | 0 | 0 | Against |
No total is shown for the institutional-manager reports: their sum exceeds the company's reported shares outstanding. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.
Forte Biosciences, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 17,722,893 for, 3,182 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 21 asset managers below reported 4,830,725 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,110,516 | 0 | 0 | 0 | For |
| Fidelity | 775,581 | 0 | 0 | 0 | For |
| ALGER FUNDS | 761,825 | 0 | 0 | 0 | For |
| Vanguard | 693,844 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 241,730 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 56,452 | 0 | 0 | 0 | For |
| Russell Investments | 50,051 | 0 | 0 | 0 | For |
| Alger ETF Trust | 33,002 | 0 | 0 | 0 | For |
| ALGER FUNDS II | 32,341 | 0 | 0 | 0 | For |
| Lord Abbett | 32,292 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 10,200 | 0 | 0 | 0 | For |
| Charles Schwab | 9,864 | 0 | 0 | 0 | For |
| American Century | 8,576 | 0 | 0 | 0 | For |
| Empower | 6,691 | 0 | 0 | 0 | For |
| Equitable | 5,362 | 0 | 0 | 0 | For |
| Victory Capital | 1,246 | 0 | 0 | 0 | For |
| Texas Capital Funds Trust | 607 | 0 | 0 | 0 | For |
| BlackRock | 268 | 0 | 0 | 0 | For |
| John Hancock | 208 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 67 | 0 | 0 | 0 | For |
| Guggenheim | 2 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 13,885,668 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Federated Hermes | 15.20% |
| 2 | Fidelity | 5.59% |
| 3 | ALGER FUNDS | 5.49% |
| 4 | Vanguard | 5.00% |
| 5 | ALGER PORTFOLIOS | 1.74% |
| 6 | ALGER INSTITUTIONAL FUNDS | 0.41% |
| 7 | Russell Investments | 0.36% |
| 8 | Alger ETF Trust | 0.24% |
| 9 | ALGER FUNDS II | 0.23% |
| 10 | Lord Abbett | 0.23% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 19.67% |
| 2 | Federated Hermes | 15.20% |
| 3 | ORBIMED ADVISORS LLC | 11.36% |
| 4 | FRED ALGER MANAGEMENT, LLC | 9.02% |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.98% |
| 6 | MPM BioImpact LLC | 6.85% |
| 7 | Affinity Asset Advisors, LLC | 6.46% |
| 8 | Woodline Partners LP | 5.92% |
| 9 | Fidelity | 4.51% |
| 10 | Citadel | 3.47% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities Affiliated with OrbiMed | — | DEF14A |
| Entities Affiliated with Janus Henderson Investors US LLC | — | DEF14A |
| Entities Affiliated with Federated Hermes, Inc. | — | DEF14A |
| Entities Affiliated with Alger Associates, Inc. | — | DEF14A |
| Entities Affiliated with Tybourne Strategic Opportunities Fund II LP | — | DEF14A |
| JANUS HENDERSON GROUP PLC | — | 13G |
| ORBIMED ADVISORS LLC | — | 13G |
| Affinity Asset Advisors, LLC | — | 13G |
| MPM BioImpact LLC | — | 13G |
| Alger Associates, Inc. | — | 13G |
Percentages above are of 13,885,668 shares outstanding, as reported by Forte Biosciences, Inc. on its Form 10-K dated March 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Forte Biosciences, Inc.’s 10-K dated March 27, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Forte Biosciences, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Forte Biosciences, Inc. 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/forte-biosciences-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.